Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98


Risk Haplotypes Uniquely Associated with Radioiodine-Refractory Thyroid Cancer Patients of High African Ancestry.

Hurst Z, Liyanarachchi S, He H, Brock P, Sipos J, Nabhan F, Kebebew E, Green P, Cote GJ, Sherman S, Walker CJ, Chang YS, Xue S, Hollingsworth B, Li W, Genutis L, Menq E, de la Chapelle A, Jhiang SM.

Thyroid. 2019 Apr;29(4):530-539. doi: 10.1089/thy.2018.0687. Epub 2019 Feb 13.


Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.

Li J, Liang J, Zhao T, Lin Y.

Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1034-9. doi: 10.1007/s00259-015-3305-1. Epub 2016 Jan 16.


Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases.

Sabra MM, Dominguez JM, Grewal RK, Larson SM, Ghossein RA, Tuttle RM, Fagin JA.

J Clin Endocrinol Metab. 2013 May;98(5):E829-36. doi: 10.1210/jc.2012-3933. Epub 2013 Mar 26.


Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer Cells.

Cheng W, Liu R, Zhu G, Wang H, Xing M.

J Clin Endocrinol Metab. 2016 Mar;101(3):962-71. doi: 10.1210/jc.2015-3433. Epub 2016 Jan 11.


Clinical outcomes of low-dose and high-dose postoperative radioiodine therapy in patients with intermediate-risk differentiated thyroid cancer.

Jeong JH, Kong EJ, Jeong SY, Lee SW, Cho IH, Ah Chun K, Lee J, Ahn BC.

Nucl Med Commun. 2017 Mar;38(3):228-233. doi: 10.1097/MNM.0000000000000636.


Association of specific PTEN/10q haplotypes with endometrial cancer phenotypes in African-American and European American women.

Sutton J, Orloff MS, Michener C, Chiesa-Vottero A, Prayson R, Nowacki AS, Eng C.

Gynecol Oncol. 2015 Aug;138(2):434-40. doi: 10.1016/j.ygyno.2015.05.024. Epub 2015 May 28.


Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.

Bae JS, Kim Y, Jeon S, Kim SH, Kim TJ, Lee S, Kim MH, Lim DJ, Lee YS, Jung CK.

Diagn Pathol. 2016 Feb 9;11:21. doi: 10.1186/s13000-016-0458-6.


Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.

Narayanan S, Colevas AD.

Curr Treat Options Oncol. 2016 Jun;17(6):30. doi: 10.1007/s11864-016-0404-6. Review.


Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.

Chakravarty D, Santos E, Ryder M, Knauf JA, Liao XH, West BL, Bollag G, Kolesnick R, Thin TH, Rosen N, Zanzonico P, Larson SM, Refetoff S, Ghossein R, Fagin JA.

J Clin Invest. 2011 Dec;121(12):4700-11. doi: 10.1172/JCI46382. Epub 2011 Nov 21.


Targetable gene fusions identified in radioactive iodine refractory advanced thyroid carcinoma.

van der Tuin K, Ventayol Garcia M, Corver WE, Khalifa MN, Ruano Neto D, Corssmit EPM, Hes FJ, Links TP, Smit JWA, Plantinga TS, Kapiteijn E, van Wezel T, Morreau H.

Eur J Endocrinol. 2019 Apr 1;180(4):235-241. doi: 10.1530/EJE-18-0653.


Combined BRAFV600E analysis and 99mTc-MIBI scintigraphy can be a useful diagnostic tool in differentiated thyroid cancer patients with incomplete bio-chemical response to first radioiodine therapy (RAIT): a pilot investigation.

Campennì A, Ruggeri RM, Siracusa M, Pignata SA, Di Mauro F, Vento A, Trimarchi F, Baldari S.

J Endocrinol Invest. 2018 Nov;41(11):1283-1288. doi: 10.1007/s40618-018-0864-6. Epub 2018 Mar 16.


Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.

Zou M, Baitei EY, Alzahrani AS, BinHumaid FS, Alkhafaji D, Al-Rijjal RA, Meyer BF, Shi Y.

Thyroid. 2014 Aug;24(8):1256-66. doi: 10.1089/thy.2013.0610. Epub 2014 Jun 10.


TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer.

Yang X, Li J, Li X, Liang Z, Gao W, Liang J, Cheng S, Lin Y.

J Nucl Med. 2017 Feb;58(2):258-265. doi: 10.2967/jnumed.116.180240. Epub 2016 Aug 4.


Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?

Ibrahimpasic T, Nixon IJ, Palmer FL, Whitcher MM, Tuttle RM, Shaha A, Patel SG, Shah JP, Ganly I.

Surgery. 2012 Dec;152(6):1096-105. doi: 10.1016/j.surg.2012.08.034.


BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.

Kakavand H, Walker E, Lum T, Wilmott JS, Selinger CI, Smith E, Saw RP, Yu B, Cooper WA, Long GV, O'Toole SA, Scolyer RA.

Histopathology. 2016 Oct;69(4):680-6. doi: 10.1111/his.12992. Epub 2016 Jun 15.


Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib.

Ali SM, He J, Carson W, Stephens PJ, Fiorillo J, Lipson D, Palmer GA, Ross JS, Miller VA, Sharman J.

Case Rep Oncol. 2014 May 24;7(2):343-8. doi: 10.1159/000363377. eCollection 2014 May.


Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low- and intermediate-risk papillary thyroid cancer.

Orlov S, Salari F, Kashat L, Freeman JL, Vescan A, Witterick IJ, Walfish PG.

Endocrine. 2015 Sep;50(1):130-7. doi: 10.1007/s12020-015-0575-0. Epub 2015 Mar 20.


Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.

Piccardo A, Puntoni M, Bottoni G, Treglia G, Foppiani L, Bertoli M, Catrambone U, Arlandini A, Dib B, Altrinetti V, Massollo M, Bossert I, Cabria M, Bertagna F, Giovanella L.

Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):926-934. doi: 10.1007/s00259-016-3593-0. Epub 2016 Dec 14.


Supplemental Content

Support Center